Takeda is to set up four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg as part of its strategic global expansion effort. Mexico represents the world's 12th largest pharma market and accounts for around 25% of the pharmaceutical sales in Latin America. Turkey comes in at number 13 worldwide (sixth in Europe) and has the fastest forecasted growth rate in Europe over the next five years. Norway, Sweden, Denmark, Belgium and Luxembourg combined account for 5% of the European pharmaceutical market. The new subsidiaries will strengthen Takeda's expansion efforts for products such as Actos (pioglitazone), which the company bought back in October last year.
Alan MacKenzie, Takeda's EVP. International Operations, commented: "Executing our territory expansion strategy is an important step toward further globalizing our operations and enhancing our ability to bring important medicines to patients who need them."
Click here for Takeda Europe CEO Erich Brunn's take on the global expansion strategy.